Table 4.
The 3-year clinical outcomes according to prognostic factors.
| Factor | Overall survival (%) | p | Disease-specific survival (%) | p | Disease-free survival (%) | p | Locoregional control (%) | p | Distant metastasis-free survival (%) | p |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | ||||||||||
| ≤50/>50 | 78/85 | 0.61 | 78/89 | 0.24 | 66/72 | 0.59 | 72/74 | 0.97 | 93/98 | 0.18 |
| Gender | ||||||||||
| Male/Female | 84/51 | 0.1 | 86/60 | 0.32 | 71/42 | 0.51 | 74/56 | 0.9 | 97/80 | 0.14 |
| pT | ||||||||||
| pT1-2/pT3-4 | 87/75 | 0.08 | 89/79 | 0.15 | 72/66 | 0.65 | 73/73 | 0.88 | 98/92 | 0.13 |
| pN | ||||||||||
| pN0/pN1-3 | 96/33* | a | 98/34* | a | 81/32* | a | 81/46* | a | 100/79* | A |
| Pathology stage | ||||||||||
| I-II/III-IV | 98/66* | a | 100/69* | a | 81/58* | 0.01 | 81/65 | 0.07 | 100/92* | 0.04 |
| Grade | ||||||||||
| 1/2+3 | 83/81 | 0.99 | 100/83 | 0.35 | 100/67 | 0.17 | 100/71 | 0.2 | 100/96 | 0.63 |
| Surgical margin | ||||||||||
| (+)/(-) | 63/83 | 0.26 | 63/86 | 0.16 | 44/71 | 0.21 | 44/75 | 0.12 | 100/96 | 0.63 |
| ≤2/>2 (mm) | 64/94* | 0.02 | 66/97* | 0.01 | 59/93* | b | 64/97* | b | 91/97 | 0.37 |
| ≤3/>3 (mm) | 70/91 | 0.18 | 71/95 | 0.09 | 67/91 | 0.06 | 71/95* | 0.04 | 93/95 | 0.74 |
| ECS | ||||||||||
| (+)/(-) | 25/77* | a | 33/77* | b | 50/71* | 0.01 | 75/73 | 0.62 | 75/76 | 0.02 |
| PNI | ||||||||||
| (+)/(-) | 72/85 | 0.23 | 72/80 | 0.15 | 64/71 | 0.32 | 73/73 | 0.64 | 91/96 | 0.41 |
| Bone invasion | ||||||||||
| (+)/(-) | 85/91 | 0.2 | 85/91 | 0.2 | 55/70 | 0.46 | 55/74 | 0.3 | 100/98 | 0.63 |
| Skin invasion | ||||||||||
| (+)/(-) | 76/94 | 0.19 | 82/94 | 0.48 | 56/64 | 0.78 | 67/64 | 0.27 | 84/100 | 0.05 |
*, Statistically significant difference; a, p < 0.001; b, p < 0.01; PNI, perineural invasion; ECS, extracapsular spread; (+), positive; (-), negative.